Deficiency or activation of peroxisome proliferator-activated receptor α reduces the tissue concentrations of endogenously synthesized docosahexaenoic acid in C57BL/6J mice

Wen-Ting Hsiao, Hui-Min Su, Kuan-Pin Su, Szu-Han Chen, Hai-Ping Wu, Yi-Ling You, Ru-Huei Fu and Pei-Min Chao

1Department of Nutrition, China Medical University, 91 Hsueh-Shih Road, Taichung 404, Taiwan
2Graduate Institute of Physiology, National Taiwan University, Taipei 100, Taiwan
3Department of Psychiatry and Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung 404, Taiwan
4Graduate Institute of Immunology, China Medical University, Taichung 404, Taiwan

BACKGROUND/OBJECTIVES: Docosahexaenoic acid (DHA), an n-3 long chain polyunsaturated fatty acid (LCPUFA), is acquired by dietary intake or the in vivo conversion of α-linolenic acid. Many enzymes participating in LCPUFA synthesis are regulated by peroxisome proliferator-activated receptor alpha (PPARα). Therefore, it was hypothesized that the tissue accretion of endogenously synthesized DHA could be modified by PPARα.

MATERIALS/METHODS: The tissue DHA concentrations and mRNA levels of genes participating in DHA biosynthesis were compared among PPARα homozygous (KO), heterozygous (HZ), and wild type (WT) mice (Exp I), and between WT mice treated with clofibrate (PPARα agonist) or those not treated (Exp II). In ExpII, the expression levels of the proteins associated with DHA function in the brain cortex and retina were also measured. An n3-PUFA depleted/replenished regimen was applied to mitigate the confounding effects of maternal DHA.

RESULTS: PPARα ablation reduced the hepatic Acox, Fads1, and Fads2 mRNA levels, as well as the DHA concentration in the liver, but not in the brain cortex. In contrast, PPARα activation increased hepatic Acox, Fads1, Fads2, and Elovi5 mRNA levels, but reduced the DHA concentrations in the liver, retina, and phospholipid of brain cortex, and decreased mRNA and protein levels of the brain-derived neurotrophic factor in brain cortex.

CONCLUSIONS: LCPUFA enzyme expression was altered by PPARα. Either PPARα deficiency or activation-decreased tissue DHA concentration is a stimulus for further studies to determine the functional significance.

Keywords: PPAR alpha, clofibrate, docosahexaenoic acids, brain-derived neurotrophic factor, fatty acid desaturases

INTRODUCTION

Docosahexaenoic acid (DHA), an important n-3 long chain polyunsaturated fatty acid (LCPUFA), is involved in a range of physiological functions across tissues that affect the human lifespan. During the perinatal period, DHA indispensably contributes to brain, neuron and retinal development; irreversible defects occur in its absence [1-3]. Furthermore, DHA is essential for normal spermatogenesis, as a deficiency causes male infertility [4]. With the substantiated functions in hypo-triglyceridemia, anti-coagulation, vasodilation, and anti-inflammation, DHA protects against cardiovascular diseases [5-7]. Moreover, it has been consistently reported that decreased DHA concentrations in the human brain and peripheral tissues are associated with a range of brain disorders, including cognitive and learning impairment, depression, bipolar disease, and attention deficit hyperactivity [8-11]. In addition to being derived from eating marine-based foods, DHA can be synthesized endogenously by conversion from the essential fatty acid α-linolenic acid (C18:3, n-3). This involves alternating desaturation and elongation reactions shared between n-6 and n-3 PUFA. Delta-6/delta-4 desaturase (D6D) and delta-5 desaturase (D5D), which are encoded by the Fads2 and Fads1 genes, respectively, dehydrogenate on the assigned carbon [12]. Elongase 5 (Elov5), elongase 2 (Elov2), and elongase 4 (Elov4) target substrates with various chain lengths (C18/C20, C20-24 and C26-34, respectively) [13]. In 1991, a circuitous pathway (coupled microosomal-peroxisomal pathway) was suggested [14] and confirmed in fibroblast cultures from patients with peroxisome biogenesis defects [15,16].
pathway, C20 was elongated consecutively to C24 and terminated by a single round of peroxisomal β-oxidation after delta-6 desaturation (Fig. 1).

Among the genes participating in LCPUFA biosynthesis, *Fads1*, *Fads2*, *Elov5*, plus *Scd1* which is responsible for introducing a double bond at the delta-9 position of C16:0 and C18:0, are positively regulated by peroxisome proliferator-activated receptor alpha (PPARα) and sterol regulatory element-binding transcription factor 1c (SREBP-1c) [17-19]. In the last step in the circuitous pathway (peroxisomal β-oxidation), the rate limiting enzyme acyl-CoA oxidase (encoded by *Acox*), as well as enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase and thiolase, are well-recognized PPARα target genes [20]. On the other hand, the importance of PPARα in DHA biosynthesis is unclear. Conflicting results for tissue DHA accretion have been achieved when PPARα was activated pharmacologically [21-23]. Thus far, no DHA deficiency has been reported in PPARα KO mice. Despite the lack of consensus in the relative importance of these two apparently redundant pathways, the significance and non-compensation for the circuitous pathway are supported by the Zellweger syndrome decreasing the DHA concentrations dramatically [14,15] and *Elov2* KO male mice being infertile due to a DHA deficiency [13]. Based on the notion that the PPARα activity is strongly correlated with peroxisomal β-oxidation, this study examined the role of PPARα on DHA biosynthesis, because DHA-containing food is not widely available for many persons.

To this aim, two experiments were conducted: mice with differential PPARα levels (+/+, +/- and −/− genotypes; Exp I) and activities (+ PPARα agonist; Exp II). An n-3 PUFA depleted/replenished regimen was used to exclude the confounding effects of DHA passing from the mothers, via the placenta and milk. This n-3 PUFA depleted/replenished regimen has two advantages: 1) to ensure equal basal levels at the beginning (n-3 depletion); and 2) once the DHA precursor is provided, these depleted mice promptly start n3-LCPUFA synthesis. In addition to the hepatic mRNA levels of the enzymes involved in DHA biosynthesis, the tissue DHA and its associated functional proteins were measured as the outcome parameters.

**MATERIALS AND METHODS**

**Study design**

In Exp I, PPARα −/− (KO), +/- (HZ) and +/+ (WT) mice were used to test the effects of the PPARα protein levels on tissue DHA accretion. For groups KO, HZ, and WT, there were eight mice (males: females = 1:1) in each group. To deplete the tissue DHA concentrations in neonates, mice were born and nursed by dams eating a sunflower oil diet (deficient in the DHA precursor, α-linolenic acid). After weaning (3 weeks of age), the pups were fed a soybean oil diet (sufficient in α-linolenic acid) to promote DHA biosynthesis. Four weeks later (i.e. seven weeks of age), they were sacrificed by carbon dioxide asphyxiation. Aliquots of the liver and brain cortex were quick-frozen in liquid nitrogen and stored at -80°C for RNA extraction. A portion of the liver and brain cortex were stored at -20°C for fatty acid analysis.

In Exp II, to test the effects of PPARα activation on tissue DHA accretion, WT mice were used and an n-3 PUFA depleted/replenished regimen was applied. After weaning, the pups were fed a soybean oil diet, with or without 0.5% (wt./wt.) clofibrate (CF; TCI, Tokyo, Japan), a PPARα agonist. The control (C) and CF groups contained 16 mice (males: females = 1:1) in each group. The mice were sacrificed at seven weeks of age. The liver, brain cortex, and retina were collected and stored at -20°C (for RNA and protein extraction) or -80°C (for fatty acid analysis). To verify n3-PUFA depletion by the sunflower oil diet (i.e., basal fatty acid profiles), no additional batches of animals were used considering the 3Rs of animal welfare. Instead, three neonates (each from WT, KO, and HZ group, respectively) selected randomly were sacrificed at weaning for fatty acid analysis in the liver. No α-linolenic acid, EPA and DHA were detectable with a detection limit ≥ 0.1%.
Mice breeding, genotyping and diet

Heterozygous PPARα mice were produced by mating homozygous PPARα-null (B6;129S4-Ppardtm1Gor/J) male mice with a pure C57BL/6J genetic background, and their wild-type female counterparts, which were both purchased from Jackson Lab (Bar Harbor, ME, USA). When these heterozygous mice were at least eight weeks of age, they were mated to produce KO, HZ and WT (expected ratio, 1:2:1) genotypes, which was confirmed by PCR of mouse tail DNA, according to the instructions from Jackson Lab (Fig. S1). The litter size was adjusted to 6-8 with equal numbers of both sexes.

The composition of diets followed the AIN93M [24] with dietary fat modified from 4 to 10% (wt./wt.) and a reciprocal reduction in corn starch. Dietary fat came from either sunflower oil (Taiwan Sugar Corporation, Tainan, Taiwan) with an n-6/n-3 ratio > 200, or soybean oil (President, Tainan, Taiwan), with an n-6/n-3 ratio ≅ 7 because a high n-6/n-3 ratio deteriorates the endogenous synthesis of DHA [25]. No dietary DHA was provided in the feed. Table S1 lists the feed composition. All mouse were kept in a room maintained at 23 ± 2°C with a controlled 12-h light-dark cycle with access to food and drinking water ad libitum. The body weight was recorded weekly and the food intake was recorded every other day. The protocols for animal care and handling were approved by the Institutional Animal Care and Use Committee of China Medical University (IRB No. 104-130-N).

Lipid extraction, phospholipid isolation and fatty acid analysis

The total lipids were extracted from the tissues (liver, brain cortex, and retina) using a 2:1 mixture of methanol/chloroform. As phospholipids are dominant in the brain and neurons, the phospholipid fraction was isolated further from the total lipid of the brain cortex in Exp. II using an SPE column (CHROMABOND NH2) (Merck, Dueren, Germany). This was not feasible for retina lipids because there were only trace amounts of samples, even when pooled from four mice within a group. Extracts were taken to dryness and weighed to estimate the total lipid content. The total lipids or phospholipid fraction was subjected to transesterification by overnight incubation at 3°C/min to 230°C, and held at 230°C for 5 min. The fatty acid peaks were identified by a comparison of the retention time; the body weight and food intake were similar in the three groups (WT, HZ and KO) across the experimental interval (data not shown).

In accordance with a PPARα deficiency, the hepatic mRNA levels of the PPARα target genes, Acox and Cyp4a10 were reduced significantly in the HZ and KO mice compared to the WT mice, with a genotype-dependent effect evident for Cyp4a10 (Fig. 2A). For hepatic desaturases (Fads1, Fads2 and Scd1) and elongases (Elovl2 and Elovl5), the PPARα deficiency reduced the mRNA levels of Fads2, Fads1, and Scd1, but not Elovl2 and Elovl5 (Fig. 2B).
Regardless of whether it was in the liver or brain cortex, there was no difference in total lipid concentration among the WT, HZ and KO groups (22 ± 8 mg/g in liver and 55 ± 18 mg/g in brain cortex) (Table S3). The fatty acid composition of the total lipids extracted from the liver and brain cortex are shown (Table S3). Attention was paid to three LCPUFA, DHA, eicosapentaenoic acid (EPA), and arachidonic acid (AA)%. Hepatic DHA and AA were reduced significantly in KO but not in HZ mice; there were only 50% of those in the WT and HZ counterparts (Fig. 3A).

On the other hand, in the brain cortex, KO reduced only AA, but there were no differences in DHA and EPA among the three genotypes (Fig. 3B).

PPARα activation on tissue DHA accretion and function (Exp II)

Clofibrate reduced the body weight and food intake during the treatment period (postweaning). Hepatomegaly, a hallmark of the peroxisome proliferator effect in rodents, was present in the CF group at the end point (6.7 ± 0.4 vs 4.1 ± 0.4%, P <
Fig. 5. DHA, EPA and AA percentage in the total lipid of liver (A), phospholipids of brain cortex (B) and total lipid of retina (C). Hepatic mRNA levels of Cpt1α and Ehhadh are shown in (D). Data are the mean ± SD, n=16 (for A, B, and D) or 4 (for C). *P<0.05, **P<0.01, ***P<0.0001. C, control mice; CF, clofibrate-treated mice. DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; AA, Arachidonic acid.

Fig. 6. mRNA levels of gene encoding proteins associated with DHA transportation and functions in brain cortex (A) and retina (B). (C) shows BDNF protein levels in brain cortex. Data are the mean ± SD, n = 16. (A) and (B). The comparison was based on the mRNA levels relative to the C group (taken as 1). *P<0.05, ***P<0.0001. C, control mice; CF, clofibrate-treated mice. BDNF, brain-derived neurotrophic factor.
0.05; liver/body weight ×100% of CF and C group), confirming PPARα activation.

In accordance with PPARα activation, the hepatic mRNA levels of Acox and Cyp4a10 were increased significantly by CF with 1.8- and 3.4-fold induction, respectively (Fig. 4A). With the exception of Elovl2, CF increased the mRNA levels of all desaturases and elongases to varying degrees (Fig. 4B). In brain cortex, however, the mRNA levels of these enzymes were unaffected (data not shown).

The total lipid concentration in the liver of group CF was 40% lower than that of group C (Table S4). No difference in the total phospholipid concentration was found in the brain cortex of the two groups. The total lipid content in the retina was not measured because of the trace amounts of specimen. The fatty acid composition in the total lipids of the liver and retina, as well as in the phospholipid of the brain cortex, are shown (Table S4). Treatment with CF caused 18, 24, and 55% decreases in the DHA% in the liver (Fig. 5A), brain cortex (Fig. 5B), and retina (Fig. 5C), respectively. Hepatic EPA and AA% were also reduced by CF. To test the fatty acid catabolism, the expression of genes participating in mitochondrial or peroxisomal β-oxidation were measured (Fig. 5D). The hepatic mRNA levels of Cpt1a (encoding carnitine palmitoyltransferase 1A) and Ehhadh (encoding enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase or L-bifunctional enzyme) were greater in the CF group than in the C group.

For the genes associated with DHA transportation and function, the mRNA levels of Mfsd2a, Ngf, and Ntrk2 in the brain cortex (Fig. 6A), as well as Mfsd2a, Pax6, Cx3, Opn1sw, Opn1mw, Opn1lw, and Rho in the retina (Fig. 6B) were similar in the control and CF groups. On the other hand, there was a significant decrease in the transcript (Fig. 6A) and protein levels (Fig. 6C) of BDNF in the brain.

**DISCUSSION**

Although the rate of α-linolenic acid conversion to DHA is quite low in humans (estimated to be < 0.1% in men and 9% in women) [32], it is important for people with limited access to marine foods or DHA supplements. This study focused on PPARα impacts on DHA (and other LCPUFA) accretion because the PPARα activity can be altered by factors in foods, medicines, and gene polymorphisms. As expected, expressions of the enzymes involved in LCPUFA synthesis were down- or up-regulated, respectively, with a PPARα deficiency or activation. On the other hand, both scenarios led to reduced DHA accretion. Among the proteins associated with DHA transport or function in the brain and retina, there were lower levels of neurotransphin BDNF mRNA and protein in an n-3 PUFA depleted/replenished model of CF-treated mice.

PPARα could be regarded as a cellular fatty acid sensor, which upon activation, increased not only transport and β-oxidation of fatty acids, but also lipogenesis (with collaboration with SREBP-1c) to protect the liver from cytotoxicity due to the influx of fatty acids under common stresses, e.g., fasting [21]. A battery of genes involved in LCPUFA synthesis, Fads1, Fads2 and Elovl5, plus Scd1, are upregulated by PPARα and SREBP-1c concomitantly [17-19,33]. Even the two transcription factors have reciprocal roles on the lipid metabolism (catabolism for the former and anabolism for the latter); this paradox was explained by a promise of LCPUFA production, regardless of the energy state [19]. Their mRNA change patterns were closely related to a PPARα deficiency or activation, even though the constitutive level of Elovl5 was not altered by PPARα ablation. In accordance with the suppressed Acox, Fads1, and Fads2 expression, liver n-6 and n-3 LCPUFA precursor (C18:2, n-6 and C18:3, n-3) accumulated, whereas the chain length ≥ C20 (C20:3, n-6; C20:4, n-6; C22:4, n-6; C22:5, n-6; C22:5, n-3 and C22:6, n-3) were depleted in HZ and KO mice (Table S3). In the case of PPARα activation, in response to up-regulated Acox, Fads1, Fads2, and Elovl5, C18:2, n-6 and C18:3, n-3 decreased, as expected, with variable changes in the down-stream LCPUFA (Table S4 and below).

Reduced tissue DHA accretion mediated by CF administration was in accordance with a previous report [23] showing that under the conditions of increased mitochondrial and peroxisomal proliferation, a relatively higher β-oxidation rate of n-3 LCPUFA in the mitochondria and peroxisome might decrease the hepatic concentrations of EPA and DHA. In accordance with this notion, 1.5-, 2-, 5.5- fold greater expression of Cpt1a (indicator of mitochondrial β-oxidation), Acox and Ehhadh (both indicators of peroxisomal β-oxidation), respectively, as well as 3.8-fold greater Cyp4a10 expression (indicator of microsomal ω-oxidation) were observed in the CF group than in the C group, suggesting that fatty acid clearance was accelerated by CF. DHA-CoA was a very poor substrate for mitochondrial carnitine acyltransferase-I and -II but the peroxisomal DHA-CoA oxidase increased dramatically after the peroxisome proliferator treatment [23]. Madsen et al. [23] reported the increased combustion of DHA upon PPARα activation beyond the increased biosynthesis, thereby contributing to lower accretion. On the other hand, more than simply improving the systemic lipid profile, Tian et al. [22] attributed the cardioprotective effects of CF partially to altered myocardial fatty acid composition, namely an increase in DHA and decrease in n-6 PUFA, resulting in a lower n-6/n-3 ratio. In contrast to CF-reduced concentrations of DHA in the liver, brain cortex, and retina detected in this study, whether CF has a distinct effect from other tissues on the cardiac DHA uptake or utilization remains unknown.

The conversion of ω-linolenic acid to DHA is greater in women than in men, an effect generally attributed to estrogen [34]. The reduced partition of α-linolenic acid to β-oxidation (hence, more availability of LCPUFA substrates), greater translocation of C24 from the endoplasmic reticulum to peroxisome, or higher desaturase/elongase/peroxisomal β-oxidation enzyme activity in women compared to men was proposed [32,35]. On the other hand, this sexual dimorphism on DHA accretion or enzyme activity was not apparent in the present study. A stratum of gender was conducted in this study but no significant gender effects were noted (data not shown). This might be due to the age at study termination (seven weeks, before full sexual maturity). Greater expression of Fads1 and Fads2 were reported in female rats than male rats at 14 weeks of age fed a standard chow diet [34].

DHA accounts for approximately 50-60% of the total fatty acid content within the rod outer segments of photoreceptors [36].
Although CF caused a 55% reduction in retinal DHA, the gene expression profile of the retina examined in this study was unaffected. Pax6 and Cre are indispensable for the proliferation and differentiation of photoreceptors [37,38], and DHA is a molecular cue for achieving complete differentiation [31]. In this study, the lack of difference in the Pax6 and Cre transcripts between the C and CF groups may be due to the difficulty in detecting the differential expression of the two transcription factors beyond the early stages of retinal development (perinatal period). In studies conducted in vitro, DHA enhanced the level of opsin expression [31], even though in the present study, there was no reduction in mRNA levels of Opn1sw, Opn1imw, Opn1iw, and Rho in the CF-treated mice. DHA contributes to the brain, neuron, and retinal function by the structural and signaling roles. DHA not only influences retinal gene expression by acting as a ligand for nuclear hormone receptors, it also activates the membrane-bound retinal proteins via membrane fluidity, affects the rhodopsin regeneration/stability/kinetics partly by direct binding to rhodopsin (lipid-protein interaction), and influences cellular differentiation and survival in many ways [36,39,40]. Mounting evidence suggests that reduced retinal DHA impaired the retinal function. Abnormal electroretinograms were recorded across species (mice, rats, guinea pigs, cats, and rhesus monkeys) when the retinal DHA decreased ≥ 30% [36].

The CF-mediated BDNF reduction in brain is believed to be secondary to a lower DHA concentration in the brain cortex, rather than a direct effect of CF on BDNF expression. DHA upregulates the expression of BDNF and other neurotrophins and their receptors [29]. The tight junction between capillary microvessels and the expression of ATP binding cassette efflux transporters in the blood-brain barrier make the brain impermeable to xenobiotics from circulation [41]. Clofibrate cannot cross this barrier. The reduced brain DHA accretion could be due to lower hepatic DHA levels. In line with the notion, the mRNA levels of the enzymes participating in LCPUFA synthesis (i.e., Fads1, Fads2, Elovl5, and Elovl2) in the brain cortex were unaffected by CF administration. The CF-mediated reduction in BDNF in the brain cortex was consistent with previous clinical studies, suggesting a linkage between cholesterol-lowering agents and depression and suicidality [42,43]. Epidemiological studies have described an association between lower serum cholesterol concentrations and increased suicide risk that could not be attributable entirely to depression-related malnutrition and weight loss [44,45]. Meta-analysis suggested that lowering cholesterol could cause or worsen the depressive symptoms and increase the risk of suicide [46]. On the other hand, there were inconsistent findings in that low cholesterol concentrations in depressed patients and suicidal victims might not be a direct factor [47]. Indeed, the result appeared to be contradictory to the context that PPARα has neuroprotective and neurotrophic effects based on its requirement for the hippocampal expression of plasticity-related molecules [48]. Recently, it was suggested that PPARα agonists may benefit memory/learning or have antidepressant-like effects by promoting the BDNF signaling cascade [49,50], WY14643 and fenofibrate (PPARα agonists) individually were confirmed to restore, PPARα-dependently, the acetylcholine receptor antagonist- or chronic social defeat stress-induced reductions in hippocampus BDNF, phosphorylation of MAPK-ERK, PI3K-Akt and CREB, as well as adult hippocampal neurogenesis in mice. The discrepancy might be caused by differences in experimental models, treatment agents or duration. Of course, the impact of lower BDNF on BDNF signaling will require further study.

A particular strength of this study was the use of an n-3 PUFA deleted/replenished model to eliminate the influence of maternal DHA, thereby facilitating a determination of bioconversion and tissue accretion of DHA. On the other hand, care should be taken when interpreting the CF-reduced DHA accretions observed in this study. Because the CF effects among PPARα KO, HZ and WT mice were not compared, the reductions of DHA and BDNF mediated by CF could not be ascribed solely to PPARα activation. CF might have effects other than PPARα activation; at least in a rodent liver, CF has been demonstrated to induce Cyp2b family members that are known to be regulated by the constitutive-activated receptor [51].

For future perspectives, functional tests (e.g. electroretinograms, cognitive or behavior tests), particularly with suppressed DHA accretion across tissues in CF-treated mice, should be conducted to determine the physiological significance or relevance. Moreover, this study raised a concern that DHA concentrations should be monitored when a fibrate-class hypolipidemic medicine is prescribed chronically to people with a low DHA intake.

Overall, the current study confirmed that the transcription of enzymes participating in LCPUFA biosynthesis, including Fads1, Fads2, Scd1, Elovl5, and Acox were changed in accordance with PPARα. On the other hand, tissue DHA accretion decreased in two opposing PPARα scenarios, i.e., ablation and activation. The significance in functional impairments mediated with a PPARα deficiency or activation awaits further study.

SUPPLEMENTARY MATERIALS

Table S1: Composition (g/kg) of the test diets used in this study. Table S2: Gene names and sequences of the PCR primers used in this study. Table S3: Fatty acid composition of total lipids in the liver and brain cortex of the WT, HZ and KO mice (Exp I), Table S4: Fatty acid composition of the total lipids in the liver and brain cortex of the WT, HZ and KO mice (Exp I), Table S5: Genotyping of PPARα +/+ (WT), +/- (HZ) and -/- (KO) mice (according to Genotyping Protocol Database from Jackson Lab).

ABBREVIATIONS

AA, arachidonic acid; BDNF, brain-derived neurotrophic factor; C, control; CF, clofibrate; D5D, delta-5 desaturase; D6D, delta-6/delta-4 desaturase; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HZ, heterozygous; KO, homozygous; LCPUFA, long chain polyunsaturated fatty acid; PPARα, peroxisome proliferator-activated receptor alpha; SREBP-1c, sterol regulatory element-binding transcription factor 1c; WT, wild type.
CONFLICT OF INTEREST

The authors declare no potential conflicts of interests.

ORCID

Wen-Ting Hsiao: https://orcid.org/0000-0002-4709-3174
Hui-Min Su: https://orcid.org/0000-0002-9970-4459
Kuan-Pin Su: https://orcid.org/0000-0002-4501-2502
Szu-Han Chen: https://orcid.org/0000-0001-8823-6840
Hai-Ping Wu: https://orcid.org/0000-0001-9770-6998
Yi-Ling You: https://orcid.org/0000-0003-3999-6143
Ru-Huei Fu: https://orcid.org/0000-0001-9367-1759
Pei-Min Chao: https://orcid.org/0000-0002-4846-3245

REFERENCES

1. Molloy C, Doyle LW, Makrides M, Anderson PJ. Docosahexaenoic acid and visual functioning in preterm infants: a review. Neuropsychol Rev 2012;22:425-37.
2. Echeverría F, Valenzuela R, Catalina Hernandez-Rodas M, Valenzuela A. Docosahexaenoic acid (DHA), a fundamental fatty acid for the brain: new dietary sources. Prostaglandins Leukot Essent Fatty Acids 2017;124:1-10.
3. Salem N Jr, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001;36: 945-59.
4. Iizuka-Hishikawa Y, Hishikawa D, Sasaki J, Takubo K, Goto M, Nagata K, Nakanishi H, Shindou H, Okamura T, Ito C, Toshimori K, Sasaki T, Shimizu T. Lysophosphatidic acid acyltransferase 3 tunes the membrane status of germ cells by incorporating docosahexaenoic acid during spermatogenesis. J Biol Chem 2017;292:12065-76.
5. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006;17:387-93.
6. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. J Hypertens 2002;20:1493-9.
7. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol Rev 1999;40:211-25.
8. Lin PY, Chiu CC, Huang SY, Su KP. A meta-analytic review of polysaturated fatty acid compositions in dementia. J Clin Psychiatry 2012;73:1245-54.
9. McNamara RK, Hahn CG, Jandacek R, Rider T, Tso P, Stanford KE, Richtand NM. Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry 2007;62: 17-24.
10. McNamara RK, Jandacek R, Rider T, Tso P, Stanford KE, Hahn CG, Richtand NM. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res 2008;160:285-99.
11. Chang JP, Su KP, Mondelli V, Pariente CM. Omega-3 polysaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology 2018;43:534-45.
12. Park HG, Park WJ, Kothapalli KS, Brenna JT. The fatty acid desaturase 2 (FADS2) gene product catalyzes Δ4 desaturation to yield n-3 docosahexaenoic acid and n-6 docosapentaenoic acid in human cells. FASEB J 2015;29:3911-9.
13. Pauter AM, Olsson P, Asadi A, Herslöf B, Cisikas R, Zadravec D, Jacobsson A. Elovl2 ablation demonstrates that systemic DHA is endogenously produced and is essential for lipid homeostasis in mice. J Lipid Res 2014;55:718-28.
14. Voss A, Reinhart M, Sankarappa S, Sprecher H. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J Biol Chem 1991;266:19995-20000.
15. Moore SA, Hurt E, Yoder E, Sprecher H, Spector AA. Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. J Lipid Res 1995;36:2433-43.
16. Ferdinandusse S, Denis S, Mooljar PA, Zhang Z, Reddy JK, Spector AA, Wanners RJ. Identification of the peroxisomal β-oxidation enzymes involved in the biosynthesis of docosahexaenoic acid. J Lipid Res 2001;42:1897-95.
17. Wang Y, Botolin D, Christian B, Busik J, Xu J, Jump DB. Tissue-specific, nutritional, and developmental regulation of rat fatty acid elongases. J Lipid Res 2005;46:706-15.
18. Tang C, Cho HP, Nakamura MT, Clarke SD. Regulation of human Δ6 desaturase gene transcription: identification of a functional direct repeat-1 element. J Lipid Res 2003;44:6865-9.
19. Matsuoka T, Shimano H, Yahagi N, Amemiya-Kudo M, Yoshikawa T, Hasty AH, Tamura Y, Otsuka J, Okazaki H, Iizuka Y, Takahashi A, Sone H, Gotoda T, Ishibashi S, Yamada N. Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha. J Lipid Res 2002;43:107-14.
20. Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 2000;32:187-204.
21. Oosterveer MH, Greffhorst A, van Dijk TH, Havinga R, Staels B, Kuipers F, Groen AK, Reijnoud DJ. Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice. J Biol Chem 2009;284:30234-44.
22. Tian Q, Grzemska FA, Panagiotopoulos S, Ahokas JT. Peroxisome proliferator-activated receptor alpha agonist, clofibrate, has profound influence on myocardial fatty acid composition. Chem Biol Interact 2006;160:241-51.
23. Madsen L, Freyland L, Dyray E, Helland K, Berge RK. Docosahexaenoic and eicosapentaenoic acids are differently metabolized in rat liver during mitochondria and peroxisome proliferation. J Lipid Res 1998;39:583-93.
24. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939-51.
25. Blank C, Neumann MA, Makrides M, Gibson RA. Optimizing DHA levels in piglets by lowering the linoleic acid to alpha-linolenic acid ratio. J Lipid Res 2002;43:1537-43.
26. Chang YY, Su HM, Chen SH, Hsieh WT, Chyuan JH, Chao PM. Roles of peroxisome proliferator-activated receptor α in bitter melon seed oil-corrected lipid disorders and conversion of α-ω-oleoarctic acid into rumenic acid in C57BL/6J mice. Nutrients 2016;8:E805.
27. Nguyen LN, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X, Wenk MR, Goh EL, Silver DL. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 2014;509:503-6.
28. Wong BH, Chan JP, Cazenave-Gassiot A, Poh RW, Foo JC, Galam DL, Ghosh S, Nguyen LN, Barathi VA, Yeo SW, Luu CD, Wenk MR, Silver DL. Mfsd2a is a transporter for the essential ω-3 fatty acid docosahexaenoic acid (DHA) in eye and is important for photoreceptor cell development. J Biol Chem 2016;291:10501-14.

29. Balogun KA, Cheema SK. The expression of neurotrophins is differentially regulated by ω-3 polyunsaturated fatty acids at weaning and postweaning in C57BL/6 mice cerebral cortex. Neurochem Int 2014;66:33-42.

30. Squinto SP, Stitt TN, Aldrich TH, Davis S, Blanco SM, Radziejewski C, Glass DJ, Valenzuela DM, Distefano PS, Yancopoulos GD. trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell 1991;65:885-93.

31. Garelli A, Rotstein NP, Politi LE. Docosahexaenoic acid promotes photoreceptor differentiation without altering Crx expression. Invest Ophthalmol Vis Sci 2006;47:3017-27.

32. Williams CM, Burdge G. Long-chain n-3 PUFA: plant v. marine sources. Proc Nutr Soc 2006;65:42-50.

33. Miller CW, Ntambi JM. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proc Natl Acad Sci U S A 1996;93:9443-8.

34. Kitson AP, Stroud CK, Stark KD. Elevated production of docosahexaenoic acid in females: potential molecular mechanisms. Lipids 2010;45:209-24.

35. Pawlosky R, Hibbeln J, Lane V, Wahlert C, Franhert C, Rao GS, Rao ML. The risk of acute suicidality in psychiatric inpatients increases with low plasma cholesterol. Pharmacopsychiatry 1999;32:1-4.

36. Queques G, Forte R, Souied EH. Retina and omega-3. J Nutr Metab 2011;2011:748361.

37. Hill RE, Favor J, Hogan BL, Ton CC, Saunders GF, Hanson IM, Prosser J, Jordan T, Hiestand ND, van Heyningen V. Mouse small eye results from mutations in a paired-like homeobox-containing gene. Nature 1991;354:522-5.

38. Furukawa T, Morrow EM, Li T, Davis FC, Cepko CL. Retinopathy and attenuated circadian entrainment in Crx-deficient mice. Nat Genet 1999;23:466-70.

39. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005;24:87-138.

40. Grossfield A, Feller SE, Pitman MC. A role for direct interactions in the modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc Natl Acad Sci U S A 2006;103:4888-93.

41. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drew J, Fricker G. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 2000;58:1357-67.

42. Maes M, Delanghe J, Meltzer HY, Scharpè S, D’Hondt P, Cosyns P. Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research. Acta Psychiatr Scand 1994;90:252-8.

43. Brunner J, Parhofer KG, Schwandt P, Bronisch T. Cholesterol, essential fatty acids, and suicide. Pharmacopsychiatry 2002;35:1-5.

44. Kurugi H, Takei N, Aoki H, Nanko S. Low serum cholesterol in suicide attempters. Biol Psychiatry 1997;41:196-200.

45. Papassotropoulos A, Hawellek B, Franhert C, Rao GS, Rao ML. The risk of acute suicidality in psychiatric inpatients increases with low plasma cholesterol. Pharmacopsychiatry 1999;32:1-4.

46. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.

47. Su KP, Tsai SY, Huang SY. Cholesterol, depression and suicide. Br J Psychiatry 2000;176:399.

48. Roy A, Jana M, Corbett GT, Ramaswamy S, Kordower JH, Gonzalez FJ, Pahan K. Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor α. Cell Reports 2013;4:724-37.

49. Xu H, You Z, Wu Z, Zhou L, Shen J, Gu Z. Wy14643 attenuates the scopolamine-induced memory impairments in mice. Neurochem Res 2016;41:2868-79.

50. Jiang B, Wang YJ, Wang H, Song L, Huang C, Zhu Q, Wu F, Zhang W. Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway. Br J Pharmacol 2017;174:177-94.

51. Ren H, Aleksunes LM, Wood C, Vallanat B, George MH, Kalessen CD, Corton JC. Characterization of peroxisome proliferator-activated receptor α--independent effects of PPARalpha activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor. Toxicol Sci 2010;113:45-59.